Nanocrystal technology for drug formulation and delivery

Abstract

With the development of modern technology like high throughput screening, combinatorial chemistry and computer aid drug design, the drug discovery process has been dramatically accelerated. However, new drug candidates often exhibit poor aqueous or even organic medium solubility. Additionally, many of them may have low dissolution velocity and low oral bioavailability. Nanocrystal formulation sheds new light on advanced drug development. Due to small (nano- or micro- meters) sizes, the increased surface-volume ratio leads to dramatically enhanced drug dissolution velocity and saturation solubility. The simplicity in preparation and the potential for various administration routes allow drug nanocrystals to be a novel drug delivery system for specific diseases (i.e. cancer). In addition to the comprehensive review of different technologies and methods in drug nanocrystal preparation, suspension, and stabilization, we will also compare nano- and micro-sized drug crystals in pharmaceutical applications and discuss current nanocrystal drugs on the market and their limitations.

Graphical abstract

Keywords

drug nanocrystal / nanotechnology / formulation / bioavailability / stabilizers / drug delivery

References

[1] Lipinski C. Poor aqueous solubility-an industry wide problem in drug discovery. American Pharmaceutical Review, 2002, 5: 82–85

[2] Peters K, Muller R H. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size reduction technique. International Journal of Pharmaceutics, 1998, 160(2): 229–237

[3] Fromming K H S, Fromming J. Cyclodextrines in Pharmacy. Dordrecht: Kluwer Academic, 1993

[4] Muller R H. Dispersions for the formulation of slightly or poorly soluble drugs. US Patent, 7060285, 2001

[5] Muller B W, Rasenack N. Micro-size drug particles: Common and novel micronization techniques. Pharmaceutical Development and Technology, 2003, 9: 1–13

[6] Zhang D, Chen M, Gao L. Drug nanocrystals for the formulation of poorly solubledrugs and its application as a potential drug delivery system. Journal of Nanoparticle Research, 2008, 10(5): 845–862

[7] Park J Y, Zhang Y, Liu F. Targeted cancer therapy with novel high drug-loading nanocrystals. Journal of Pharmaceutical Sciences, 2010, 99(8): 3542–3551

[8] Luna I P, Sutradhar K B, Khatun S. Increasing possibilities of nanosuspension. Journal of Nanotechnology, 2013, 346581: 1–12

[9] Abhijit A D, Kulkarni R M, Patravale V B. Nanosuspensions: A promising drug delivery strategy. Journal of Pharmacy and Pharmacology, 2004, 56(7): 827–840

[10] Moschwitzer J P, Muller R H, Sinha B. Bottom-up approaches for preparing drug nanocrystals: Formulations and factors affecting particle size. International Journal of Pharmaceutics, 2013, 453(1): 126–141

[11] Merisko-Liversidge E, Liversidge G G, Cooper E R. Nanosizing: a formulation approach for poorly-water-soluble compounds. European Journal of Pharmaceutical Sciences, 2003, 18(2): 113–120

[12] Parmentier J, Widzinski M, Tan E H, Gokkhale R, Chin W W L. A brief literature and patent review of nanosuspensions to a final drug product. Journal of Pharmaceutical Sciences, 2014, 103(10): 2980–2999

[13] Möschwitzer J P. Drug nanocrystals in the commercial pharmaceutical development process. International Journal of Pharmaceutics, 2013, 453(1): 142–156

[14] Cundy G G, Bishop K C, Czekai J F, Liversidge D A. Surface modified drug nanoparticles. US Patent, 5145684, 1992

[15] Muller R H, Shegokar R. Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives. International Journal of Pharmaceutics, 2010, 399(1-2): 129–139

[16] Liversidge E M, Merisko-Liversidge G G. Drug nanoparticles: Formulating poorly water-soluble compounds. Toxicologic Pathology, 2008, 36(1): 43–48

[17] Muller R H, Keck C M. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 62(1): 3–16

[18] Muller R H, Moschwitzer J P, Salazar J. Combinative particle size reduction technologies for the production of drug nanocrystals. Journal of Pharmaceutics, 2014, 265754: 1–14

[19] Rabinow B E. Nanosupensions in drug delivery. Nature Reviews. Drug Discovery, 2004, 3(9): 785–796

[20] Gohla S, Keck C M, Muller R H. State of the art of nanocrystals—Special features, production, nanotoxicology aspects and intracellular delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 78(1): 1–9

[21] Haynes D H. Phospholipid-coated microcrystals: Injectable formulations of water insoluble drugs. US Patent, 5091187, 1992

[22] Williams H D, Trevaskis N L, Charman S A, Shanker R M, Charman W N, Pouton C W, Porter C J H. Strategies to address low drug solubility in discovery and development. Pharmacological Reviews, 2013, 65(1): 315–499

[23] Liversidge G G, Merisko-Liversidge E. Nanosizing for oral and parenteral drug delivery: A perspective on formulating poorly-water soluble compounds using wet media milling technology. Advanced Drug Delivery Reviews, 2011, 63(6): 427–440

[24] Muller R H, Junghanns J U A H. Nanocrystal technology, drug delivery and clinical applications. International Journal of Nanomedicine, 2008, 3(3): 295–309

[25] Sucker H, Gassmann P. Improvements in pharmaceutical compositions. European Patent, 0580690, 1992

[26] List M, Sucker H. Pharmaceutical colloidal hydrosols for injection. GB Patent, 2200048, 1988

[27] Sharma S, Aggarwal G. Novel technologies for oral delivery of poorly soluble drugs. Research Journal of Pharmaceutical. Biological and Chemical Sciences, 2010, 1(4): 292–305

[28] Bohn H, Auweter H, Heger R, Precipitated water-insoluble colorants in colloid disperse form. US Patent, 6494924, 2002

[29] Auweter H, Andr’e V, Horn D, Luddecke E. The function of gelatin in controlled precipitation processes of nanosize particles. Journal of Dispersion Science and Technology, 1998, 19(2-7): 163–184

[30] Chan H K, Kwok P C. Production methods for nanodrug particles using the bottom-up approach. Advanced Drug Delivery Rivew, 2011, 63(6): 406–416

[31] Pacharane S, Chaudhry A, Jadhav K, Kadam V, Koshy P. Drug particle engineering of poorly water soluble drugs. Der Pharmacia Lettre, 2010, 2(4): 65–76

[32] Kaerger J S, Price R. kaerger J S, Price R. Processing of spherical crystalline particles via a novel solution atomization and crystallization by sonication (SAXS) technique. Pharmaceutical Research, 2004, 21(2): 372–381

[33] Wang Y H, Guo F, Wang X M, Zheng C, Chen J F. Synthesis of nanoparticles with novel technology: High-gravity reactive precipitation. Industrial & Engineering Chemistry Research, 2000, 39(4): 948–954

[34] Zhang J Y, Shen Z G, Zhong J, Yun J, Chen J F. Preparation and characterization of amorphous cefuroxime axetil drug nanoparticles with novel technology: High-gravity antisolvent precipitation. Industrial & Engineering Chemistry Research, 2006, 45(25): 8723–8727

[35] Brown J, Chen X, Swinnea S, Williams R O III, Johnston K P, Sarkari M. Enhanced drug dissolution using evaporative precipitation into aqueous solution. International Journal of Pharmaceutics, 2002, 243(1-2): 17–31

[36] Sahoo N G, Li L, Judeh Z, Wang Y, Chong K, Loh L, Kakran M. Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension. International Journal of Pharmaceutics, 2010, 383(1-2): 285–292

[37] Singh S K, Nagpal K, Girotra P. Supercritical fluid technology: A promising approach in pharmaceutical research. Pharmaceutical Development and Technology, 2013, 18(1): 22–38

[38] Montes A, Gordillo M D, Pereyra C, Martinez de la Ossa E J. Particles formation using supercritical fluids. In: Hironori Nakajima, ed. Mass Transfer-Advanced Aspects, 2011, 461–480

[39] Turk M. Manufacture of submicron drug particles with enhanced dissolution behaviour by rapid expansion processes. Journal of Supercritical Fluids, 2009, 47(3): 537–545

[40] Martín Á, Mattea F, Varona S, Cocero M J. Encapsulation and co-precipitation processes with supercritical fluids: Fundamentals and applications. Journal of Supercritical Fluids, 2009, 47(3): 546–555

[41] Kalani M, Yunus R. Application of supercritical antisolvent method in drug encapsulation: A review. International Journal of Nanomedicine, 2011, 6: 1429–1442

[42] Rogers T L, Brown J, Young T, Johnston K P, Williams R O III, Hu J. Improvement of dissolution rates of poorly water soluble APIs using novel spray freezing into liquid tecnology. Pharmaceutical Research, 2002, 19(9): 1278–1284

[43] Moschwitzer J, Muller R H. New method for the effective production of ultrafine drug nanocrystals. Journal of Nanoscience and Nanotechnology, 2006, 6(9-10): 3145–3153

[44] Wong J C T, Doty M J, Rebbeck C L, Kipp J E. Microprecipitation method for preparing submicron suspensions. US Patent, 6869617, 2001

[45] Muller R H, Moschwitzer J. Method and device for producing very fine particles and coating such particles. US Patent, 0297565 A1, 2009

[46] Gokhale R, Burgess D J, Verma S. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. International Journal of Pharmaceutics, 2009, 380(1-2): 216–222

[47] Keck C M, Kobierski S, Mauludin R, Muller R H. Second generation of drug nanocrystals for delivery of poorly soluble drugs: Smart crystal technology. Dosis, 2008, 24(2): 124–128

[48] Mchwitzer R H, Bushrab J, Muller F N. Manufacturing of nanoparticles by milling and homogenization techniques. In: Gupta R B, Kompella U B, eds. Nanoparticle Technology for Drug Delivery. New York: CRC Press, 2006, 59: 21–51

[49] Reddy I K, Nutan M T H. General Principles of Suspensions. In: Kulshreshtha A K, Singh O N, Wall G M, eds. Pharmaceutical Suspensions. New York: Springer-Verlag, 2009, 39–65

[50] Heinzerling O, Salazar J, Muller R H, Moschwitzer J P. Process of optimization of a novel production method for nanosuspensions using design of experiments. International Journal of Pharmaceutics, 2011, 420(2): 395–403

[51] Zhang J, Watanabe W, Wu L. Physical and chemical stability of drug nanoparticles. Advanced Drug Delivery Reviews, 2011, 63(6): 456–469

[52] Landau B V, Derjaguin L. Theory of the stability of strongly charged lyophobic sols and of the adhesion of strongly charged particles in solutions of electrolytes. Acta Physico-Chimica Sinica, 1941, 14: 633–662

[53] Van den Mooter G, Augustijns P, Van Eerdenbrugh B. Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. International Journal of Pharmaceutics, 2008, 364(1): 64–75

[54] Wang Z H, Li T L, Lu Y. Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation. Journal of Controlled Release, 2014, 176: 76–85

[55] Liu R. Water-Insoluble Drug Formation. Buffalo Grove: Inter-Pharm Press, 2000, 455

[56] Tian W, Zhang Y, Sun W, He J, Mao S, Fang L. Effect of novel stabilizers-cationic polymers on the particle size and physical stability of poorly soluble drug nanocrystals. Nanomedicine; Nanotechnology, Biology, and Medicine, 2012, 8(4): 460–467

[57] Yoo J Y, Kwak H S, Choi J Y. Role of polymeric stabilizers for drug nanocrystal dispersions. Current Applied Physics, 2005, 5(5): 472–474

[58] Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. Journal of Pharmacy and Pharmacology, 2010, 62(11): 1569–1579

[59] Chase A R, Gibson G D, Granberg M R, Harvey C B, King S C, Martin R E, Medwick A N, Swinyard T, Zink E A, Gennaro G L. Colloidal dispersions. In: Alfonso R G, ed. Remington’s Pharmaceutical Sciences. Philadelphia: Mack Publishing Co., 1985, 286–289

[60] Hartenhauer N, Muller R H, Rasenack B W. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. International Journal of Pharmaceutics, 2003, 254(2): 137–145

[61] Muller N, Rasenack B W. Dissolution rate enhancement by in-situ-micronization of poorly water-soluble drugs using a controlled crystallization process. Pharmaceutical Research, 2002, 19: 1896–1902

[62] Chandrasekhar V S R, Katteboinaa S. Drug nanocrystals: a novel formulation approach for poorly soluble drugs. International Journal of Pharm Tech Research, 2009, 1(3): 682–694

[63] Whitney W R, Noyes A A. The rate of solution of solid substances in their own solutions. Journal of the American Chemical Society, 1897, 19(12): 930–934

[64] Mehta S C, Higuchi W I, Simonelli A P. Inhibition of sulfathiazole crystal growth by polyvinylpyrrolidone. Journal of Pharmaceutical Sciences, 1970, 59: 633–638

[65] Ponchel G, Duchene D. Bioadhesion of solid oral dosageforms, why and how? European Journal of Pharmaceutics and Biopharmaceutics, 1997, 44(1): 15–23

[66] Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, Kawashima Y, Lehr C M. Biodegradable nanoparticles for targeted drug delivery intreatment ofinflammatory bowel disease. Journal of Pharmacology and Experimental Therapeutics, 2001, 299(2): 775–781

[67] Jaitley V, Florence A T, Hussain N. Recent advancesin the understanding of uptake of microparticulates acrossthe gastrointestinallymphatic. Advanced Drug Delivery Reviews, 2001, 50(12): 107–142

[68] Muller R H, Jacobs C. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharmaceutical Research, 2002, 19(2): 189–194

[69] Gangwal R P, Sangamwar A T, Jain S, Thanki K. Oral delivery of anticancer drugs: Challenges and opportunities. Journal of Controlled Release, 2013, 170(1): 15–40

[70] Jacobs C, Kayser O, Muller R H. Production and characterisation of muco adhesive nanosuspensions for the formulation of bupravaquone. International Journal of Pharmaceutics, 2001, 214(1-2): 3–7

[71] Conzentino G G, Liversidge P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. International Journal of Pharmaceutics, 1995, 125(2): 309–313

[72] Engers W M, Mueller D A, Eickhoff K R. Nanoparticulate NSAID Compositions, Application. US Patent, 5518738 A, 1996

[73] Kayser O, Olbrich C, Yardley V, Kiderlen A F, Croft S L. Formulation of amphotericin B as nanosuspension for oral administration. International Journal of Pharmaceutics, 2003, 254(1): 73–75

[74] Tu Z, Ng C, Yang Y, Liang J F, Agresti C. Specific interactions between diphenhydramine and alpha-helical poly(glutamic acid)-a new ion-pairing complex for taste masking and pH-controlled diphenhydramine release. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70(1): 226–233

[75] Garg A, Aggarwal D, Singla A K. Paclitaxel and its formulations. International Journal of Pharmaceutics, 2002, 235(1-2): 179–192

[76] Peters K, Leitjke S, Diederichs J E, Borner K, Hahn H, Muller R H, Ehlers S. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. Journal of Antimicrobial Chemotherapy, 2000, 45(1): 77–83

[77] Kayser O, Steckel H, Muller R H, Hernandez-Trejo N. Characterization of nebulised buparvaquone nanosuspension—effect of nebulization technology. Journal of Drug Targeting, 2005, 13(8-9): 499–507

[78] Kayser O, Muller R H, Steckel H, Hernandez-Trejo N. Physical stability of buparvaquone nanosuspensions following nebulization with jet and ultrasonic nebulizers. In: Proceedings of the International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Nuremberg Germany, 2004

[79] Montisci M J, Dembri A, Ponchel G, Durrer C, Duchene D. Mucoadhesion of colloidal particulate systems in the gasrointesinal tract. European Journal of Pharmaceutics and Biopharmaceutics, 1997, 4: 25–31

[80] Aggarwal P, Hall J B, McLeland C B, Dobrovolskaia M A, McNeil S E. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Advanced Drug Delivery Reviews, 2009, 61(6): 428–437

[81] Liu Y, Huang L, Liu F. Paclitaxel nanocrystals for overcoming multidrug resistance in cancer. Molecular Pharmaceutics, 2010, 7(3): 863–869

[82] Kayser O. Nanosuspensions for the formulation of aphidicolin to improve drug targeting effects against Leishmania infected macrophages. International Journal of Pharmaceutics, 2000, 196(2): 253–256

[83] Mansell P. Nanocrystals could be route to carrier-free drug delivery. in-Pharma, 2007

[84] Singh Y, Meher J G, Pawar V K, Gupta S, Chourasia M K. Engineered nanocrystal technology: In-vivo fate, targeting and applications in drug delivery. Journal of Controlled Release, 2014, 183: 51–66

[85] Bansal M, Kumria R, Bansal S. Nanocrystals: Current strategies and trends. International Journal of Research in Pharmaceutical and Biomedical Sciences, 2012, 3(1): 406–419

Acknowledgements

This study was supported by NIH Grant GM081874.

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg